Onychomycosis Treatment Guidelines

Introduction to Treatment

The British Journal of Dermatology recommends fluconazole administration for onychomycosis treatment, with dosage and duration varying based on the type of nail infection 1

The recommended dosage of fluconazole is 150-450 mg once weekly, with treatment duration of 3-9 months depending on the type of nail infection, and potentially extendable to 9 months for better outcomes in toenail infections, as suggested by the British Journal of Dermatology 1

Baseline assessments should include liver function tests, complete blood count, and renal function evaluation, with dose adjustment necessary in renal impairment, and monitoring of liver function tests is recommended for patients on high-dose or prolonged therapy 1
Common adverse effects include headache, skin rash, gastrointestinal complaints, and insomnia, leading to treatment discontinuation in up to 58% of patients receiving higher weekly doses (300-450 mg) 1

Fluconazole is considered a second-line treatment option, with terbinafine and itraconazole recommended as first-line treatments due to superior efficacy, as suggested by the British Journal of Dermatology and the American Academy of Dermatology 1, 2
Mycological cure rates for fluconazole are 89-100% for fingernail infections and 47-62% for toenail infections, while clinical cure rates are 76-90% for fingernail infections and 28-36% for toenail infections 1
Higher doses (450 mg) and longer treatment duration (9 months) are associated with significantly better outcomes, and fluconazole has a long half-life, allowing for once-weekly dosing, and it remains detectable in nails for up to 6 months after discontinuation 1
As a weaker inhibitor of cytochrome P450 enzymes compared to itraconazole, fluconazole results in fewer drug interactions, though caution is still necessary with concomitant medications metabolized by CYP450 enzymes 1
Despite not being FDA-approved specifically for onychomycosis, fluconazole has substantial clinical evidence supporting its use, particularly in cases where first-line treatments are not suitable, with the guideline society recommending terbinafine or itraconazole as first-line treatment for onychomycosis due to their superior efficacy 1, 2